The antibacterial effects (ABE) of tomopenem (formerly RO4908463/CS-023) against seven Staphylococcus aureus strains (methicillin-resistant S. aureus [MRSA] strain tomopenem MICs, 0.5 to 16 mg/liter; methicillinsensitive S. aureus [MSSA] strain tomopenem MIC, 0.06 mg/liter) were studied in an in vitro pharmacokinetic model. Initially, two human doses were simulated, 750 mg every 8 hours (8hly) and 1,500 mg 8hly intravenously, using S. aureus at a standard inoculum of 10 6 CFU/ml. There was a rapid clearance of bacteria from the model by 12 h after drug exposure with most strains. Clearance was not related to the tomopenem MIC. The ABE of these two tomopenem dose regimens were also tested at a high inoculum, 10 8 CFU/ml; in all simulations, there was a >4-log drop in viable count at 24 h. Strains were not cleared from the model at 10 8 CFU/ml, in contrast to what was seen for the standard inoculum. When the ABE of tomopenem at 750 mg 8hly was compared to those of vancomycin, tomopenem was seen to have a superior effect, as measured by the area under the bacterial kill curve at 24 h (AUBKC 24 ) and 48 h (P < 0.05). Dose ranging studies were performed to provide time-above-MIC (T>MIC) drug exposures of 0 to 100% (8 to 10 doses per strain) with five MRSA/MSSA strains. The T>MIC for a 24-h bacteriostatic effect was 8% ؎ 5% (range, 1.3% to 15.4%); the T>MIC for a 4-log drop in viable count was 32% ؎ 18% (range, 12.8% to 36.2%). The T>MIC for a 90% maximum response using AUBKC 24 as ABE was 24.9% ؎ 15.7%. Inoculum had little impact on T>MIC exposures for ABE. There was emergence of resistance to tomopenem in the dose ranging studies, with increased growth of subpopulations on plates containing tomopenem at 2؋ and 4؋ the MIC compared to what was seen for preexposure population analysis at T>MICs of <20%. The pharmacodynamics of tomopenem against S. aureus is similar to those of other members of the carbapenem class, with the exception that MRSA is included. These data indicate that tomopenem will have clinically useful activity against MRSA at T>MICs achievable in humans.
Tomopenem (formerly RO4908463/CS-023) is an injectable 2-substituted 1-␤-methyl carbapenem. It has a guanidine-pyrrolidine side chain and binds with high affinity to penicillin binding protein 1 (PBP1), PBP2, and PBP4 from Staphylococcus aureus. The MIC 50 and MIC 90 against methicillin-sensitive S. aureus (MSSA) are 0.12 and 0.12 to 0.25 mg/liter (17, 19, 32) . For methicillin-resistant S. aureus (MRSA), the MIC 50 and MIC 90 are 2 and 4 to 16 mg/liter (17, 19, 32) . This contrasts to imipenem and meropenem, which have MRSA MIC 90 values of 32 and 16 to 32 mg/liter. Tomopenem retains in vitro potency against extended-spectrum ␤-lactamase-producing Escherichia coli and Klebsiella spp. as well as Pseudomonas aeruginosa (8, 17, 19, 33) .
The pharmacokinetics studies with male healthy volunteers indicate relatively typical carbapenem pharmacokinetics except for a prolonged serum half-life of about 2 h, which is related to a lack of renal tubular secretion (29) . Tomopenem is stable to digestion by human renal DHP-1 (18) and produces peak serum concentrations of about 44 mg/liter after a 700-mg dose and 100 mg/liter after a 1,400-mg dose in humans (29) . Around 70% of the dose is excreted unchanged in the urine, but a pharmacologically inactive open ring metabolite (R131624) has been described (30) . Protein binding in humans is Ͻ10% (29) and the volume of distribution is 15 to 17 liters. Autoradioluminograms of animals injected with 14 C-tomopenem indicated wide tissue distribution except for the cerebrospinal fluid and testes (30) .
The aim of this study is to describe the antibacterial effects (ABE) of tomopenem against a range of MRSA strains at high and low inocula, establish the time-above-MIC (TϾMIC)-ABE relationship, and compare the effects of tomopenem to vancomycin. The impact of the maximum concentration of drug in serum/MIC and area under the concentration-time curve/MIC on ABE was not studied.
A dilutional single-compartment in vitro pharmacokinetic model was used.
MATERIALS AND METHODS
In vitro pharmacokinetic model. A New Brunswick (Hatfield, Hertfordshire, England) Bioflo 1000 in vitro pharmacokinetic model was used to simulate free drug serum concentrations associated with dosings of tomopenem and vancomycin. The apparatus, which has been described before, consists of a single central chamber connected to a reservoir containing broth. The central chamber is connected to a collecting vessel for overflow (23) . The contents of the central chamber were diluted with broth by using a peristaltic pump (Ismatec, Bennett & Co, Weston-super-Mare, England) at a flow rate of 132 ml/h for tomopenem and 47.9 ml/h for vancomycin. The temperature was maintained at 37°C and the broth in the central chamber was agitated by a magnetic stirrer.
Media. Ten-percent Mueller-Hinton broth (MHB) was used in experiments with both tomopenem and vancomycin. Previous experiments had shown that 10% broth was able to sustain the growth of S. aureus and produced consistent and reproducible results in the model systems. Nutrient agar plates (Oxoid, Basingstoke, England) were used to recover S. aureus from the in vitro model. Five microliters ␤-lactamase/ml was used to neutralize tomopenem. The ␤-lactamase neutralized tomopenem up to a concentration of 100 mg/liter. Tomopenem was added to nutrient agar plates in the studies on the emergence of resistance.
Strains. Six MRSA strains of S. aureus were provided by M. Jones, Eurofins Medinet Inc., Herndon, VA. The tomopenem MICs ranged from 0.5 to 16 mg/liter for MRSA strains. An MSSA strain MIC of 0.06 mg/liter was used for comparison.
Antibiotics. Tomopenem was supplied by Hoffman-La Roche Inc., Nutley, NJ. Vancomycin was supplied by Alpharm Ltd., Basingstoke, England. Stock solutions were prepared according to British Society of Antimicrobial Chemotherapy guidelines (7) and stored at Ϫ70°C.
MICs. MICs were determined by a standard broth dilution method according to CLSI guidelines (9) . MICs were performed in 10% MHB and at nondoubling dilutions to more accurately determine MICs.
Pharmacokinetics. A number of tomopenem free drug simulations were performed. The pharmacokinetic parameters simulated were associated with the following doses of intravenous tomopenem: 750 mg every 8 hours (8hly) and 1,500 mg 8hly with maximum concentrations of free drug in serum of 45 mg/liter and 90 mg/liter and a serum half-life of 2 h. Six doses were given over 48 h. In addition, between 7 and 13 doses were simulated per strain in a dose ranging design to achieve a TϾMIC range of 0 to 100% for each strain in experiments to determine the TϾMIC-ABE relationship.
Free drug concentrations associated with 1 g intravenous vancomycin given 12hly were an initial peak of 15 mg/liter and a trough at 12 h of 3.8 mg/liter, with a half-life of 6 h (22) . Drug concentrations for tomopenem were determined using a bioassay method (4) . For tomopenem, the indicator organism was E. coli NCTC 10418, the medium was Penassay seed agar with wells, the standard curve range was 2 to 128 mg/liter, and the limit of detection was 0.5 mg/liter. The coefficient of variation was 12.2%. Vancomycin was assayed by polarization fluoroimmunoassay (Abbott, Berkshire, England). The coefficient of variation was 5.9%.
ABE. Experiments were performed at inoculum densities of 10 6 CFU/ml and 10 8 CFU/ml with tomopenem. For the 10 6 inoculum, 720 l of a 10
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-CFU/ml bacterial suspension from a 24-h plate culture was added to the sample chamber 45 min before dosing. For the 10 8 inoculum, 1 ml of 0.5 McFarland standard prepared from a 24-h plate culture was added to the central chamber and the model run overnight. Samples were taken throughout the 48-h period for determination of viable counts. Bacteria were quantified by using a spiral plater (Don Whitley Spiral Systems, West Yorkshire, United Kingdom). The minimum level of detection was 10 2 CFU/ml. Additional aliquots were also stored at Ϫ70°C for measurement of the antibiotic concentration using bioassay (4) and polarization fluoroimmunoassay.
Emergence of resistance. Resistance to tomopenem was assessed as before using population analysis profiles (22) at time zero (preexposure) and at 24 h and 48 h (postexposure). Samples were plated onto agar containing no antibiotic and antibiotic at 1ϫ, 2ϫ, 4ϫ, and 8ϫ the MIC to quantify any resistant subpopulation. The limit of detection of growth was 2 log 10 .
All pharmacokinetic simulations of human doses to determine ABE and the emergence of resistance were performed at least in triplicate.
Pharmacodynamics and measurement of ABE. The ABE of the antibiotics were calculated by determining the log change in viable counts between time zero and 12 h (⌬12), 24 h (⌬24), 36 h (⌬36), and 48 h (⌬48). The times for the inoculum to fall to 99% and 99.9% of its value at time zero were recorded as T99 and T99.9, respectively. The area under the bacterial kill curve (AUBKC; log CFU/ml ⅐ h) was calculated using the log-linear trapezoidal rule for the periods 0 to 24 h (AUBKC 0-24 ) and 0 to 48 h (AUBKC 0-48 ). The relationship between TϾMIC and ABE was delineated using sigmoid Emax models (GraphPad Prism; GraphPad Software Incorporated, San Diego, CA).
RESULTS

MICs and initial tomopenem population analysis profiles.
The tomopenem MICs by CLSI methods and in 10% MHB are shown on Table 1 . The MICs in 10% MHB were significantly lower than the MICs by conventional CLSI methods. When TϾMIC was calculated for tomopenem in the in vitro model, the MICs in 10% MHB were used. The vancomycin MICs for MRSA strains 33922, 33827, and 33815 were 1.5, 0.5, and 0.25 mg/liter, respectively. The population analysis profiles for each MRSA strain with tomopenem are also shown on Table 1 . These indicated some variability in the population profiles before the strains are exposed to tomopenem. Strains with similar MICs but differing population analysis profiles were selected for study in the in vitro pharmacokinetic model. Pharmacokinetic curves and pharmacodynamic parameters. There was good agreement between target and achieved tomopenem and vancomycin concentrations. In all situations, the measured antibiotic concentration 95% confidence interval (CI) limits encompassed the target concentration (data not shown).
The TϾMICs for the 750-mg 8hly and 1,500-mg 8hly simulations were 100% for all strains except MRSA 33820 and 33815. The TϾMICs for both strains with the 750-mg 8hly simulations were 73% and with the 1,500-mg 8hly simulation were 98%.
ABE: tomopenem human dose simulations of 750 mg 8hly and 1,500 mg 8hly. The first series of simulations was performed with tomopenem at an initial inoculum of 10 6 CFU/ml against the MSSA strain and all six MRSA strains. Irrespective of tomopenem MIC, rapid clearance occurred in the model, with counts being undetectable by 12 h with all strains except MRSA 33921 ( Table 2) .
Analysis of variance of the AUBKC 0-24 and AUBKC 0-48 for the 750-mg 8hly simulations indicated no significant differences between the strains (P Ͼ 0.05). A similar analysis of the 1,500-mg 8hly simulation indicated that strain MRSA 33815 had a smaller AUBKC 0-24 and AUBKC 0-48 than the other strains (P Ͻ 0.001). This indicates that tomopenem had a greater activity against this strain than the others tested. There was no difference between the ABE of the 750-mg 8hly simulations and the 1,500-mg 8hly simulations.
The ABE of tomopenem was also tested against three strains (33922, 33827, and 33815) at a high inoculum (10 8 CFU/ml). At the higher inoculum, S. aureus was not cleared from the model, even over 48 h later (Table 3) . However, in all cases, a Ͼ4 log 10 drop in viable count was observed by 24 h with minimal growth back up to 48 h. As might be expected, the times to clear 99% or 99.9% of the initial inoculum were longer with the high inoculum, as were the AUBKC 0-24 and AUBKC 0-48 , compared to what was seen for equivalent experiments at 10 6 CFU/ml (Table 3) . ABE: vancomycin. Vancomycin did not result in clearance by 24 h from the model challenged at a 10 6 -CFU/ml inoculum; there was a 1.5-to 3-log 10 drop in viable counts with the three MRSA strains tested (Table 4) . Only with one strain, MRSA 33827, did clearance occur at 48 h. When the ABE of vancomycin and tomopenem were compared in terms of AUBKC 0-24 and AUBKC 0-48 , then tomopenem had an ABE superior to that of vancomycin (P Ͻ 0.05).
Dose ranging. A range of doses (n ϭ 8 to 11) was used to provide a TϾMIC range of 0 to 100% for each strain at an inoculum of 10 6 CFU/ml. ABE was measured by ⌬24, ⌬48, AUBKC 0-24 , and AUBKC 0-48 for each strain and related to TϾMIC in a sigmoid Emax model. Using ⌬24 as the main ABE measure, the TϾMIC for static effect was 8% Ϯ 5% (95% CI, 2.0% to 13%), increasing to 32% Ϯ 18% (95% CI, 9% to 55%) for a 4-log drop in count (Table 5 ; Fig. 1 ).
TϾMIC could also be related to ⌬48 and AUBKC 0-24 or AUBKC 0-48 at an R of Ͼ0.9 for each strain. The TϾMIC to produce a 90% maximum response using AUBKC 0-24 as the ABE was 23% Ϯ 13% (95% CI, 9% to 36%). The TϾMIC to produce a 4-log drop in count at 48 h was 27% Ϯ 28% (95% CI, 43% to 98.4%) and a 90% maximum response using AUBKC 0-48 as ABE was 25% Ϯ 16% (95% CI, 8% to 41%).
A range of doses (n ϭ 7 to 13) was also modeled at a higher (10 8 -CFU/ml) inoculum for MSSA strain 5965 and for three MRSA strains, 22922, 33817, and 33815. A static-effect TϾMIC cannot be usefully calculated in these experiments, as 10 8 CFU/ml is the maximum supportable inoculum in the model, beyond which no further growth occurs. The TϾMIC to produce a 1-log 10 drop in viable count was 6.4% Ϯ 8.7% of the dosing interval by use of ⌬24 as the ABE measure ( Table 6 ). The TϾMIC to produce a 4-log drop at 24 h was 30.1% Ϯ 33.1% of the dosing interval.
Emergence of resistance to tomopenem. With the 750-mg and 1,500-mg 8hly simulations at 10 6 CFU/ml, there was no emergence of resistance as there was clearance from the models. At the 10 8 -CFU/ml initial inoculum, no S. aureus organisms were recovered from antibiotic plates containing 4ϫ the MIC of tomopenem (MIC-ϫ4 plates) or above.
In the dose ranging studies, emergence of resistance was noted in some experiments. At an initial inoculum of 10 6 CFU/ ml, no strains produced subpopulations able to grow on MIC-ϫ2 plates prior to dosing with tomopenem.
After 24 h of exposure, all strains except MRSA 33815 produced growth on MIC-ϫ2 plates (Fig. 2) . Only MRSA 33922 and MRSA 33927 produced subpopulations able to grow on MIC-ϫ4 plates (Fig. 2) . A score of 2 logs for Fig. 2 indicates no growth on the MIC-ϫ2 or MIC-ϫ4 plates. Bacterial counts of Ͼ2 logs were noted primarily with TϾMICs of Ͻ25%. The lower the TϾMIC, the higher the bacterial count (Fig. 2) . The pattern of growth on tomopenem after 48 h exposure was similar to that at 24 h except for MSSA 5956, MRSA 33922, and MRSA 33927, which produced subpopulations capable of growth on MIC-ϫ4 plates.
At the higher inoculum (10 8 CFU/ml), growth was noted on MIC-ϫ2 plates prior to drug dosing with strains MSSA 5956 and MRSA 33827. Growth on MIC-ϫ4 plates was noted at 24 h with MSSA 5956 and MRSA 33827 and was also noted for MIC-ϫ8 plates at 48 h. There was a clear relationship between TϾMIC and growth on MIC-ϫ2 or MIC-ϫ4 plates at 24 h and 48 h, with TϾMIC values of Յ20 to 30% being much more likely to produce resistant subpopulations.
DISCUSSION
The pharmacodynamics of ␤-lactams and in particular carbapenems are well understood (10) . Carbapenems show concentration-dependent killing at concentrations of up to 8 to 16 times the pathogen MIC (13) but not at high concentrations (15) and also show persistent antibiotic effects in animal and in vitro experiments (5, 16, 26, 32) . The postantibiotic effect is related to both the concentration of carbapenem employed and the duration of pathogen exposure (27) . There is a lack of inoculum effect on antibacterial activity compared to other ␤-lactams (28) . The dominant pharmacodynamic index is TϾMIC for both gram-positive and gram-negative bacteria (6, 15, 16, 20, 34) , as shown in in vitro and in vivo pharmacodynamic models.
The pharmacodynamics of carbapenems against S. aureus follows this pattern, showing concentration-dependent killing FIG. 2 . TϾMIC relationship to growth on MIC-ϫ2 and MIC-ϫ4 plates after 24 h with a 10 6 inoculum (data from all strains were pooled). at low concentrations (14) but not high, with a longer postantibiotic effect than against E. coli (16). TϾMIC drives ABE (1) .
The initial part of this study was to describe the ABE of tomopenem against a range of MRSA strains with MICs from 0.5 to 16 mg/liter. Two dosing regimens were simulated, 750 mg or 1,500 mg 8hly intravenously. Both regimens produced rapid clearance of all MRSA strains and the single MSSA strain from the model at a standard inoculum. It was not possible to relate clearance to initial strain MIC. Previous work simulating human serum carbapenem concentrations against MSSA has shown significant ABE in in vitro models, with 3-to 4-log drops in viable counts up to 6 h and 4-to 5-log drops at 12 to 24 h (6, 11, 14, 24, 25) . Our data are in keeping with this, with the exception that the strains we used were mainly MRSA.
Increasing the initial bacterial inoculum from 10 6 CFU/ml to 10 8 CFU/ml resulted in around a 5-log reduction in count by 24 h with approximately 3 to 4 log units of bacteria being detected to 48 h. This has also been observed when meropenem was tested against MSSA at an initial inoculum of 10 8 CFU/ml (6) .
There is clinical evidence to suggest that ␤-lactam antibiotics such as isoxazyl penicillins (penicillinase-resistant penicillins) may offer advantages over vancomycin in the therapy of human MSSA infection (21, 31) . Recently, this has been related to the high in vitro and in vivo activity of cloxacillin compared to that of vancomycin (12) . Our comparison of tomopenem with vancomycin by use of three strains of MRSA clearly indicated that tomopenem had an ABE superior to that of vancomycin in terms of clearance of pathogens from the model.
The second part of the study employed a dose ranging design to determine the TϾMIC for a range of ABE. These data indicated that for both 10 6 and 10 8 CFU/ml inocula, the TϾMIC for a 1-to 2-log drop in viable count at 24 h was on average 10 to 20% of the dosing interval, with the maximum response occurring at about 30% of the dosing interval. Of importance, however, is the strain-to-strain variation in TϾMIC which results in significant spread from mean TϾMICs. These values are somewhat lower than some TϾMICs reported for animal models with S. aureus and doripenem, where the static effect occurred in the range from 27 to 35% and a 2-log kill was between 31 and 41%. In contrast, the anti MRSA carbapenem PZ601 had a TϾMIC of 8% Ϯ 5% for a static effect against S. aureus, including MRSA, and required a TϾMIC of 19.5% Ϯ 3.47% for a 2-log kill (2) . These values are very close to those reported here. In addition, animal studies of the anti-MRSA cephalosporin PPI 0903/TAK 599 indicated static-effect TϾMIC in the range from 15 to 36% and a 2-log kill between 23 and 51%; the maximum effect occurred at a free drug concentration of Ͼ40% (3). Our data are similar to these results, with a maximal effect at a free drug TϾMIC of Ͼ30% of the dosing interval being slightly lower with the carbapenem than with cephalosporin, as might be expected. Inoculum did not have an impact on the TϾMIC-ABE relationship.
Studies on emergence of resistance to carbapenems in S. aureus in in vitro pharmacokinetic models are rare. Our data indicate that at TϾMICs of Ͼ30%, the risk of resistance is very low. This contrasts to situations where the TϾMIC is Ͻ10%.
In conclusion, these preclinical pharmacokinetic model data are supportive of the use of tomopenem to treat MRSA in humans. Tomopenem shows good ABE against MRSA strains, and this effect is not impaired significantly by high inoculum. Comparative studies with vancomycin indicated superiority, while the TϾMIC for a maximum effect was around 30% and the TϾMIC for a static effect was less than 10%.
A TϾMIC target of 30% can be used to set clinical breakpoints for tomopenem against MRSA; at this level of exposure, there is little risk of the emergence of resistance.
